Reserpine changes the dynamic state of enkephalin stores in rat striatum and adrenal medulla by different mechanisms

The administration of reserpine increases enkephalin content in rat striatum and adrenal medulla. In order to investigate the mechanisms operative in this increase, we have studied in vivo the dynamic state of enkephalin stores by determining the content of proenkephalin mRNA, enkephalin precursors, and enkephalins in rats receiving reserpine. We measured proenkephalin mRNA by using a cDNA probe for human proenkephalin mRNA which hybridizes to the same species of mRNA either in the brain or in adrenal medulla. (Met5)-Enkephalin-Arg6-Phe7, as well as the high and low molecular weight forms of the enkephalins separated by Sephadex G-75 column chromatography, were measured by radioimmunoassay. Reserpine (2 mg/kg, i.p., repeated daily for two consecutive days) led 3 to 5 days later to an increase in the striatal content of proenkephalin mRNA as well as high and low molecular weight peptides containing enkephalin. The same treatment produced, in adrenal medulla, a shift from higher molecular weight to lower molecular weight enkephalin-containing peptides, an increase of enkephalin peptides, and a decrease of proenkephalin mRNA content. The results in striatum suggest that reserpine increases enkephalin synthesis by removing a tonic dopaminergic inhibition: those in adrenal medulla indicate that reserpine causes an accumulation of enkephalins by blocking the release and/or increasing the processing which may trigger a feedback-regulatory mechanism leading to a decrease in proenkephalin mRNA content.